<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>&lt;i&gt;Clostridioides difficile&lt;/i&gt; infection in children: Microbiology, pathogenesis, and epidemiology</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center"><i>Clostridioides difficile</i> infection in children: Microbiology, pathogenesis, and epidemiology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle"><i>Clostridioides difficile</i> infection in children: Microbiology, pathogenesis, and epidemiology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Crews, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maribeth R Nicholson, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Clostridioides</em> <em>difficile</em> is an important cause of antibiotic-associated diarrhea and one of the most common health care-associated pathogens [<a href="#rid1">1</a>]. Its clinical manifestations range from asymptomatic colonization or mild diarrhea to fulminant disease characterized by ileus, toxic megacolon, hypotension, or shock. <em>C. difficile</em> infection is less common in children than adults, but the incidence of <em>C. difficile</em> infection in children is increasing [<a href="#rid2">2-5</a>].</p><p>The microbiology, pathogenesis, and epidemiology of <em>C. difficile</em> infection in children will be discussed below. The clinical features, diagnosis, treatment, and prevention of <em>C. difficile</em> infection in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6050.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Treatment and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/2687.html" rel="external">"<i>Clostridioides difficile</i> infection: Prevention and control"</a>.)</p><p><em>C. difficile</em> infection in adults also is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology"</a> and  <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MICROBIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Organism</span><span class="headingEndMark"> — </span><em>C. difficile</em> is an anaerobic, gram-positive, spore-forming, toxin-producing bacillus. It<em> </em>exists in spore form in the environment. The spores are metabolically dormant and resistant to heat, acid, antibiotics, and most disinfectants. After <em>C. difficile</em> spores reach the intestine, they germinate into the vegetative form, which is capable of producing toxins and is susceptible to killing by antimicrobial agents.</p><p><em>C. difficile</em> is widely distributed in nature. It has been found in water, soil, food products, domestic and farm animals, and households [<a href="#rid6">6-10</a>]. Within health care facilities, <em>C. difficile</em> has been cultured from the hands of patients and health care personnel, hospital surfaces, medical equipment, and hospital pet therapy dogs [<a href="#rid11">11,12</a>]. <em>C. difficile</em> can persist on hospital surfaces for months [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Toxins</span><span class="headingEndMark"> — </span>Toxins A and B are the major virulence factors of <em>C. difficile</em>. They are encoded by genes (<em>tcdA</em> and <em>tcdB</em>) located on a pathogenicity locus that also contains three regulatory genes. Nontoxigenic strains lack the <em>tcdA</em> and <em>tcdB</em> genes and are nonpathogenic. Toxins A and B mediate disease by disrupting the cytoskeletal structure of intestinal epithelial cells, resulting in inflammation and cell death [<a href="#rid13">13</a>]. Toxin A ("enterotoxin") causes inflammation leading to mucosal injury and intestinal fluid secretion [<a href="#rid14">14</a>]. Toxin B ("cytotoxin") is essential for the virulence of <em>C. difficile</em> and is more potent than toxin A in mediating colonic mucosal damage [<a href="#rid15">15,16</a>]. Thus, strains lacking toxin A can be as virulent as strains with both toxins [<a href="#rid17">17,18</a>]. Fecal toxin levels may correlate with disease severity [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Toxins'</a>.)</p><p>The NAP1/BI/027 strain has unique characteristics: It possesses a deletion in the <em>tcdC</em> gene (a negative regulator of toxin production), produces a third toxin (binary toxin), and is resistant to fluoroquinolones [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'PCR ribotype 027 strain'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of <em>C. difficile</em> disease is incompletely understood. However, disease expression is known to involve [<a href="#rid21">21,22</a>] (see  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Pathophysiology'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Alteration of the colonic microbiota (usually, but not always, following antibiotic therapy)</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion, colonization, and overgrowth of <em>C. difficile</em></p><p class="bulletIndent1"><span class="glyph">●</span>Production of <em>C. difficile</em> toxin(s) (necessary but not sufficient to cause clinical disease)</p><p class="bulletIndent1"><span class="glyph">●</span>Injury to and inflammation of intestinal epithelium</p><p></p><p>Other factors may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Production of antitoxin antibodies – Adults colonized with <em>C. difficile</em> who have low or undetectable levels of antibody against toxin A are more likely to develop diarrhea than those with detectable antibody [<a href="#rid23">23</a>]. Production of antitoxin antibodies following a primary <em>C. difficile</em> infection is associated with protection against recurrent disease [<a href="#rid24">24</a>]. In addition, in randomized trials in adults with <em>C. difficile</em> infection, <a class="drug drug_pediatric" data-topicid="141999" href="/z/d/drug information/141999.html" rel="external">bezlotoxumab</a>, a monoclonal antibody against toxin B, lowered the risk of recurrent disease [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonization with nontoxigenic strains, which may afford protection against disease from toxigenic <em>C. difficile</em> [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variable expression of intestinal toxin receptors – As an example, newborn rabbits lack intestinal receptors for toxin A and are resistant to disease, whereas newborn pigs have receptors and are susceptible to <em>C. difficile</em> infection [<a href="#rid28">28,29</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H617615915"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>In 2019, active population-based surveillance in the United States estimated that the incidence of <em>C. difficile</em> infection in children &lt;18 years was 34.8 cases per 100,000 population; approximately three-quarters of cases were community associated (stool sample collected on an outpatient basis or within three days after hospital admission in a person with no documented overnight stay in a health care facility in the preceding 12 weeks) [<a href="#rid30">30</a>].</p><p>In the early 2000s, an increase in the frequency and severity of <em>C. difficile</em> infection in adults was observed in several hospitals in North America [<a href="#rid20">20,31</a>]. These hospital outbreaks were largely attributed to the NAP1/BI/027 strain [<a href="#rid20">20</a>]. Since then, the incidence of <em>C. difficile</em> infection has increased considerably. In the United States, the incidence of <em>C. difficile</em>-related hospitalizations more than doubled between 2000 and 2009 [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Epidemiology'</a>.)</p><p>Increased frequency of <em>C. difficile</em> infection has also been documented for children [<a href="#rid2">2-5,33</a>]. The highest incidence of <em>C. difficile</em> infection occurs in children one to five years old [<a href="#rid2">2,3,5</a>].</p><p>The majority of <em>C. difficile</em> infections in children are community associated. Population-based studies suggest that 70 to 75 percent of pediatric <em>C. difficile</em> infections are community associated [<a href="#rid33">33-35</a>]. Children with community-associated infection tend to be healthier and have lower rates of exposure to antibiotics and acid suppressants than children with health care-associated disease [<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H2310304"><span class="h2">Severe disease</span><span class="headingEndMark"> — </span>Children can experience severe disease and complications from <em>C. difficile</em> infection, although with significantly lower frequency than adults. Data on the frequency of severe disease in children are limited by the absence of a validated definition. Estimation of disease severity in children is inaccurate when adult criteria for severe <em>C. difficile</em> disease are applied to children [<a href="#rid38">38,39</a>].</p><p>Studies report that 3 to 7 percent of children with <em>C. difficile</em> develop a fulminant disease – hypotension or shock, ileus, or toxic megacolon [<a href="#rid37">37-40</a>]. No temporal change in the incidence of colectomy or death has been noted in hospitalized children with <em>C. difficile</em> despite the increased incidence of <em>C. difficile</em> infection [<a href="#rid2">2,4,5</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Colonization</span><span class="headingEndMark"> — </span>Asymptomatic intestinal colonization with toxigenic <em>C. difficile</em> is common in the neonatal period and infancy [<a href="#rid41">41-43</a>]. This phenomenon has two important implications:</p><p class="bulletIndent1"><span class="glyph">●</span><em>C. difficile</em> may be an incidental finding in neonates and infants with diarrhea.</p><p class="bulletIndent1"><span class="glyph">●</span>Neonates and infants may be a reservoir of <em>C. difficile</em>.</p><p></p><p class="headingAnchor" id="H1876098"><span class="h3">Neonates and infants</span><span class="headingEndMark"> — </span>Colonization with toxigenic or nontoxigenic <em>C. difficile</em> is common during the first year of life. Early acquisition during the neonatal period and acquisition later in infancy has been described [<a href="#rid44">44</a>]. Colonization generally persists for a few months, though it can persist for up to 12 months or longer [<a href="#rid44">44-46</a>]. Shifts between toxigenic and nontoxigenic strains over time have been observed [<a href="#rid47">47</a>].</p><p>The rate of colonization reported in the literature varies widely due to differences in the testing method employed and the population studied. In a meta-analysis of observational studies, the estimated proportion of colonization with toxigenic or nontoxigenic <em>C. difficile</em> increased from 15 percent (95% CI 7-25 percent) in infants &lt;7 days of age to 41 percent (95% CI 32-50 percent) in those 6 to 12 months of age, the peak age for asymptomatic colonization [<a href="#rid47">47</a>]. The estimated proportion of colonization with toxigenic <em>C. difficile</em> increased from ≤6 percent in infants &lt;3 months of age to 14 percent (95% CI 8-21 percent) in infants 6 to 12 months of age.</p><p>The most common source of <em>C. difficile</em> acquisition among hospitalized neonates and infants is the hospital environment, and the risk of colonization increases with the duration of the hospital stay [<a href="#rid43">43</a>]. Maternal-infant transmission is only rarely described [<a href="#rid42">42</a>]. Various host factors influence <em>C. difficile</em> colonization rates during infancy. Higher rates of colonization are reported in infants who are formula fed (versus breast fed), preterm (versus term), hospitalized, and recently exposed to antibiotics [<a href="#rid41">41,42,48</a>]. Studies evaluating mode of delivery and colonization status have inconsistent findings [<a href="#rid41">41,48</a>]. </p><p>Although neonates and infants frequently are colonized with toxigenic <em>C. difficile</em>, they rarely develop symptomatic disease [<a href="#rid41">41</a>]. High levels of <em>C. difficile</em> organisms and toxins (levels similar to those in adults with pseudomembranous colitis) can be found in the stools of healthy, asymptomatic neonates and infants [<a href="#rid49">49,50</a>]. The reasons for this paradox have not been fully elucidated. An absence of intestinal receptors for <em>C. difficile</em> toxins has been proposed. Additionally, in a prospective cohort study, colonization with toxigenic <em>C. difficile</em> during infancy was associated with antibody response against toxins A and B; whether these antibodies protect against <em>C. difficile</em> infection and how long they persist requires additional investigation [<a href="#rid51">51</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p>Neonates and infants may be a reservoir of <em>C. difficile</em> for vulnerable individuals. Toxigenic strains known to circulate in adults have been detected from asymptomatic infants [<a href="#rid44">44,46,48,52</a>]. Additionally, in a case-control study among adults with community-associated diarrhea, individuals with <em>C. difficile</em> infection were more likely to report contact with children ≤2 years old [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H1876105"><span class="h3">Children</span><span class="headingEndMark"> — </span>Beyond infancy, children have lower rates of colonization. By approximately two to three years of age, toxigenic strain colonization rates decrease to 6 to 8 percent, similar to rates in nonhospitalized adults [<a href="#rid47">47</a>]. Elevated colonization rates (17 to 30 percent) have been described among hospitalized children and children with malignancy, cystic fibrosis, or inflammatory bowel disease [<a href="#rid54">54-57</a>].</p><p class="headingAnchor" id="H2310378"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>In health care settings, <em>C. difficile</em> can be spread through human hands, contaminated with <em>C. difficile</em> spores, and through contamination of the health care environment [<a href="#rid22">22,58,59</a>]. Factors associated with health care acquisition of <em>C. difficile</em> include ward-level antibiotic use and assignment to a room in which a previous patient had <em>C. difficile</em> [<a href="#rid22">22,60</a>]. Although molecular studies suggest that symptomatic patients and asymptomatic carriers transmit <em>C. difficile</em> in the hospital setting [<a href="#rid61">61-63</a>], in studies from pediatric facilities, transmission from symptomatic patients appears to be uncommon [<a href="#rid64">64,65</a>]. Asymptomatic carriers may be an important source of <em>C. difficile</em> transmission without health care exposure [<a href="#rid22">22,62</a>].</p><p><em>C. difficile</em> is increasingly acquired in the community by patients without prior health care exposure, antimicrobial treatment, or other established risk factors [<a href="#rid35">35,66</a>]. Asymptomatically colonized neonates and infants may be a source of <em>C. difficile</em> transmission to adults [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Hypervirulent strains</span><span class="headingEndMark"> — </span>Data regarding the prevalence of infection with hypervirulent strains (NAP1/BI/027) in children are limited. No data have suggested outbreaks in children or increased severity associated with the NAP1/BI/027 strain. The proportion of pediatric <em>C. difficile</em> stool samples that are the NAP1/BI/027 strain has ranged from &lt;1 to 23 percent [<a href="#rid35">35,67,68</a>].</p><p class="headingAnchor" id="H13"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H14"><span class="h2">Antibiotic exposure</span><span class="headingEndMark"> — </span>Exposure to antibiotics is the single-most important risk factor for both health care-associated and community-associated <em>C. difficile</em> infection [<a href="#rid66">66,69-71</a>]. Any antibiotic may predispose to <em>C. difficile</em> infection, though the risk varies across antibiotic classes [<a href="#rid21">21,72</a>]. <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">Amoxicillin-clavulanate</a>, cephalosporins, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, and fluoroquinolones are most frequently implicated [<a href="#rid73">73</a>]. Sulfonamides, tetracyclines [<a href="#rid74">74</a>], <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a>, and aminoglycosides are infrequently implicated in children. In pediatric studies, exposure to multiple classes of antibiotics in the preceding 30 days has been associated with severe and recurrent <em>C. difficile</em> infection [<a href="#rid40">40,75</a>].</p><p><em>C. difficile</em> infection, including severe disease, can occur in children without prior antibiotics [<a href="#rid66">66,76</a>]. In large observational studies, antimicrobial exposure was absent in &gt;40 percent of cases of <em>C. difficile</em> in children [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Other risk factors</span><span class="headingEndMark"> — </span>Proton pump inhibitors, and to a lesser extent histamine-2 receptor antagonists, have been associated with an increased risk of <em>C. difficile</em> infection in children and adults [<a href="#rid66">66,77-80</a>]. Gastrointestinal feeding devices (ie, gastrostomy or jejunostomy tubes) have also been associated with <em>C. difficile</em> infection in children [<a href="#rid37">37,70</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Predisposing conditions</span><span class="headingEndMark"> — </span>A number of medical conditions are associated with <em>C. difficile </em>infection in children.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy </strong>– Malignancy is the most common chronic condition among hospitalized children with <em>C. difficile</em> infection, accounting for 20 to 25 percent of hospital-based cases [<a href="#rid2">2,4,81</a>]. Children with malignancy and <em>C. difficile</em> infection have longer lengths of stay and higher rates of in-hospital mortality compared with children with malignancy without <em>C. difficile</em> infection [<a href="#rid82">82,83</a>]. They also have increased rates of recurrence [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1">Several factors may predispose pediatric oncology patients to <em>C. difficile</em> infection: repeated exposures to broad-spectrum antibiotics, receipt of chemotherapy, and frequent visits to health care facilities. Variation in the risk of <em>C. difficile</em> infection has been reported across antibiotic classes for pediatric oncology patients [<a href="#rid82">82,85</a>]. As an example, in a multicenter cohort, among antipseudomonal antibiotics, <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a> and <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a> were independently associated with <em>C. difficile</em> infection, while antipseudomonal penicillins and carbapenems were not [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplantation</strong> – Pediatric hematopoietic and solid organ transplant recipients have an increased risk of <em>C. difficile</em> infection [<a href="#rid86">86</a>].<strong> </strong><em>C. difficile</em> infection is common following hematopoietic transplantation. In a single-center study, 17 percent of pediatric hematopoietic transplant recipients were diagnosed with <em>C. difficile</em> infection during the 100 days posttransplant [<a href="#rid87">87</a>]. Among solid organ transplant recipients, the incidence of <em>C. difficile</em> infection varies with the transplanted organ. It is highest with pancreatic and intestinal transplantation and lowest with renal transplantation [<a href="#rid88">88</a>]. Calcineurin inhibitors and antibiotic exposure have been associated with <em>C. difficile</em> infection in pediatric solid organ transplant recipients [<a href="#rid89">89,90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory bowel disease</strong><em> – </em>Children with inflammatory bowel disease (IBD) have a higher rate of symptomatic <em>C. difficile</em> infection and higher rate of recurrence than the general pediatric population [<a href="#rid84">84,91-94</a>]. Hospitalizations related to <em>C. difficile</em> infection are increasing among children with IBD [<a href="#rid92">92</a>]. Among children hospitalized with IBD, <em>C. difficile</em> infection is associated with longer stays, increased need for parenteral nutrition, and increased blood transfusions [<a href="#rid92">92</a>]. <em>C. difficile </em>infection also has been associated with exacerbations of IBD in children [<a href="#rid91">91-93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cystic fibrosis</strong> – Children with cystic fibrosis may be predisposed to <em>C. difficile</em> infection because of their increased exposure to antibiotics and health care settings. Asymptomatic carriage of toxigenic <em>C. difficile</em> appears to be common in children with cystic fibrosis and occurs more frequently than <em>C. difficile</em> infection [<a href="#rid95">95</a>]. However, severe <em>C. difficile</em> infection with typical findings of pseudomembranous colitis has been documented [<a href="#rid57">57,96-98</a>]. (See  <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">"Cystic fibrosis: Overview of gastrointestinal disease", section on 'Distal intestinal obstruction syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hirschsprung disease</strong> – Children with Hirschsprung disease, and other disorders of gut motility, may be susceptible to <em>C. difficile</em> infection due to colonic stasis, changes in mucosal defense, and altered colonic flora. While it is not known definitively whether <em>C. difficile</em> contributes to Hirschsprung enterocolitis, the reports of pseudomembranous colitis occurring in infants with Hirschsprung disease suggest the relationship could be causal in some cases [<a href="#rid99">99,100</a>]. (See  <a class="medical medical_review" href="/z/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis", section on 'Pseudomembranous colitis'</a> and  <a class="medical medical_review" href="/z/d/html/5891.html" rel="external">"Emergency complications of Hirschsprung disease", section on 'Enterocolitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Structural or postoperative intestinal disorders</strong> – Severe <em>C. difficile</em> disease may occur in children with structural intestinal disorders and after intestinal operations, including placement of an ileostomy. Severe enteritis should prompt consideration of <em>C. difficile</em> disease in such children, in the immediate postoperative period and any time thereafter [<a href="#rid101">101,102</a>].</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – <em>Clostridioides</em> <em>difficile</em> is an anaerobic, gram-positive, spore-forming, toxin-producing bacillus. The spore form of <em>C. difficile</em> is resistant to heat, acid, antibiotics, and most disinfectants, and can persist in the hospital environment for several months. (See <a class="local">'Organism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of <em>C. difficile</em> disease involves altered colonic microflora; <em>C. difficile</em> ingestion, colonization, and overgrowth; toxin production; and toxin injury of intestinal epithelial cells, resulting in inflammation and diarrhea. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colonization</strong> – Asymptomatic <em>C. difficile</em> colonization is common among neonates and infants, peaking between 6 and 12 months of age. Given the high frequency of asymptomatic colonization, <em>C. difficile</em> may be an incidental finding in neonates and infants with diarrhea. (See <a class="local">'Colonization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Antibiotic use is the most important risk factor for <em>C. difficile</em> infection in children. The antibiotics most frequently implicated include <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, cephalosporins, and fluoroquinolones. A minority of cases occur without prior antimicrobial exposure. (See <a class="local">'Antibiotic exposure'</a> above.)</p><p></p><p class="bulletIndent1">Additional risk factors for <em>C. difficile</em> infection in children include gastric acid suppressants and gastrointestinal feeding devices. (See <a class="local">'Other risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predisposing conditions</strong> – Certain medical conditions may predispose to <em>C. difficile</em> infection, may increase the risk of severe <em>C. difficile</em> infection, or may be exacerbated by <em>C. difficile</em> infection. These include malignancy, hematopoietic cell or solid organ transplantation, inflammatory bowel disease, cystic fibrosis, and Hirschsprung disease. (See <a class="local">'Predisposing conditions'</a> above.)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Cooperstock, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825.</a></li><li><a class="nounderline abstract_t">Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122:1266.</a></li><li><a class="nounderline abstract_t">Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010; 16:604.</a></li><li><a class="nounderline abstract_t">Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011; 165:451.</a></li><li><a class="nounderline abstract_t">Deshpande A, Pant C, Anderson MP, et al. Clostridium difficile infection in the hospitalized pediatric population: increasing trend in disease incidence. Pediatr Infect Dis J 2013; 32:1138.</a></li><li><a class="nounderline abstract_t">Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis 2007; 13:485.</a></li><li><a class="nounderline abstract_t">Bauer MP, Kuijper EJ. Potential sources of Clostridium difficile in human infection. Infect Dis Clin North Am 2015; 29:29.</a></li><li><a class="nounderline abstract_t">Bakri MM, Brown DJ, Butcher JP, Sutherland AD. Clostridium difficile in ready-to-eat salads, Scotland. Emerg Infect Dis 2009; 15:817.</a></li><li><a class="nounderline abstract_t">Koene MG, Mevius D, Wagenaar JA, et al. Clostridium difficile in Dutch animals: their presence, characteristics and similarities with human isolates. Clin Microbiol Infect 2012; 18:778.</a></li><li><a class="nounderline abstract_t">Alam MJ, Anu A, Walk ST, Garey KW. Investigation of potentially pathogenic Clostridium difficile contamination in household environs. Anaerobe 2014; 27:31.</a></li><li><a class="nounderline abstract_t">Kim KH, Fekety R, Batts DH, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143:42.</a></li><li><a class="nounderline abstract_t">Lefebvre SL, Weese JS. Contamination of pet therapy dogs with MRSA and Clostridium difficile. J Hosp Infect 2009; 72:268.</a></li><li><a class="nounderline abstract_t">Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18:247.</a></li><li><a class="nounderline abstract_t">Lima AA, Innes DJ Jr, Chadee K, et al. Clostridium difficile toxin A. Interactions with mucus and early sequential histopathologic effects in rabbit small intestine. Lab Invest 1989; 61:419.</a></li><li><a class="nounderline abstract_t">Riegler M, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995; 95:2004.</a></li><li><a class="nounderline abstract_t">Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176.</a></li><li><a class="nounderline abstract_t">Alfa MJ, Kabani A, Lyerly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38:2706.</a></li><li><a class="nounderline abstract_t">Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 2007; 11:5.</a></li><li><a class="nounderline abstract_t">Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079.</a></li><li><a class="nounderline abstract_t">McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433.</a></li><li><a class="nounderline abstract_t">Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372:1539.</a></li><li><a class="nounderline abstract_t">Caroff DA, Yokoe DS, Klompas M. Evolving Insights Into the Epidemiology and Control of Clostridium difficile in Hospitals. Clin Infect Dis 2017; 65:1232.</a></li><li><a class="nounderline abstract_t">Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390.</a></li><li><a class="nounderline abstract_t">Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189.</a></li><li><a class="nounderline abstract_t">Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 2017; 376:305.</a></li><li><a class="nounderline abstract_t">Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 2015; 313:1719.</a></li><li><a class="nounderline abstract_t">Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351:633.</a></li><li><a class="nounderline abstract_t">Eglow R, Pothoulakis C, Itzkowitz S, et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest 1992; 90:822.</a></li><li><a class="nounderline abstract_t">Keel MK, Songer JG. The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs. Vet Pathol 2007; 44:814.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Clostridioides difficile infection (CDI) tracking. 2019 Annual Report. Available at: https://www.cdc.gov/hai/eip/cdiff-tracking.html#reports (Accessed on November 22, 2022).</li><li><a class="nounderline abstract_t">Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442.</a></li><li class="breakAll">Lucado J, Gould C, Elixhauser A. Clostridium difficile Infections (CDI) in Hospital Stays, 2009. HCUP Statistical Brief #124. January 2012. Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf (Accessed on August 10, 2015).</li><li><a class="nounderline abstract_t">Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 2013; 56:1401.</a></li><li><a class="nounderline abstract_t">McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28:140.</a></li><li><a class="nounderline abstract_t">Wendt JM, Cohen JA, Mu Y, et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics 2014; 133:651.</a></li><li><a class="nounderline abstract_t">Tschudin-Sutter S, Tamma PD, Naegeli AN, et al. Distinguishing community-associated from hospital-associated Clostridium difficile infections in children: implications for public health surveillance. Clin Infect Dis 2013; 57:1665.</a></li><li><a class="nounderline abstract_t">Crews JD, Koo HL, Jiang ZD, et al. A hospital-based study of the clinical characteristics of Clostridium difficile infection in children. Pediatr Infect Dis J 2014; 33:924.</a></li><li><a class="nounderline abstract_t">Pai S, Aliyu SH, Enoch DA, Karas JA. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS One 2012; 7:e51728.</a></li><li><a class="nounderline abstract_t">Tschudin-Sutter S, Tamma PD, Milstone AM, Perl TM. The prediction of complicated Clostridium difficile infections in children. Infect Control Hosp Epidemiol 2014; 35:901.</a></li><li><a class="nounderline abstract_t">Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe clostridium difficile infection in children. Pediatr Infect Dis J 2012; 31:134.</a></li><li><a class="nounderline abstract_t">Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr 2010; 51:2.</a></li><li><a class="nounderline abstract_t">Enoch DA, Butler MJ, Pai S, et al. Clostridium difficile in children: colonisation and disease. J Infect 2011; 63:105.</a></li><li><a class="nounderline abstract_t">Lees EA, Miyajima F, Pirmohamed M, Carrol ED. The role of Clostridium difficile in the paediatric and neonatal gut - a narrative review. Eur J Clin Microbiol Infect Dis 2016; 35:1047.</a></li><li><a class="nounderline abstract_t">Rousseau C, Poilane I, De Pontual L, et al. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis 2012; 55:1209.</a></li><li><a class="nounderline abstract_t">Adlerberth I, Huang H, Lindberg E, et al. Toxin-producing Clostridium difficile strains as long-term gut colonizers in healthy infants. J Clin Microbiol 2014; 52:173.</a></li><li><a class="nounderline abstract_t">Rousseau C, Lemée L, Le Monnier A, et al. Prevalence and diversity of Clostridium difficile strains in infants. J Med Microbiol 2011; 60:1112.</a></li><li><a class="nounderline abstract_t">Tougas SR, Lodha N, Vandermeer B, et al. Prevalence of Detection of Clostridioides difficile Among Asymptomatic Children: A Systematic Review and Meta-analysis. JAMA Pediatr 2021; 175:e212328.</a></li><li><a class="nounderline abstract_t">Stoesser N, Eyre DW, Quan TP, et al. Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains. PLoS One 2017; 12:e0182307.</a></li><li><a class="nounderline abstract_t">Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981; 81:5.</a></li><li><a class="nounderline abstract_t">Stark PL, Lee A, Parsonage BD. Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study. Infect Immun 1982; 35:895.</a></li><li><a class="nounderline abstract_t">Kociolek LK, Espinosa RO, Gerding DN, et al. Natural Clostridioides difficile Toxin Immunization in Colonized Infants. Clin Infect Dis 2020; 70:2095.</a></li><li><a class="nounderline abstract_t">Stoesser N, Crook DW, Fung R, et al. Molecular epidemiology of Clostridium difficile strains in children compared with that of strains circulating in adults with Clostridium difficile-associated infection. J Clin Microbiol 2011; 49:3994.</a></li><li><a class="nounderline abstract_t">Wilcox MH, Mooney L, Bendall R, et al. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008; 62:388.</a></li><li><a class="nounderline abstract_t">Leibowitz J, Soma VL, Rosen L, et al. Similar proportions of stool specimens from hospitalized children with and without diarrhea test positive for Clostridium difficile. Pediatr Infect Dis J 2015; 34:261.</a></li><li><a class="nounderline abstract_t">Burgner D, Siarakas S, Eagles G, et al. A prospective study of Clostridium difficile infection and colonization in pediatric oncology patients. Pediatr Infect Dis J 1997; 16:1131.</a></li><li><a class="nounderline abstract_t">Hourigan SK, Chirumamilla SR, Ross T, et al. Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:2744.</a></li><li><a class="nounderline abstract_t">Theunissen C, Knoop C, Nonhoff C, et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis 2008; 10:240.</a></li><li><a class="nounderline abstract_t">Samore MH, Venkataraman L, DeGirolami PC, et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996; 100:32.</a></li><li><a class="nounderline abstract_t">Bobulsky GS, Al-Nassir WN, Riggs MM, et al. Clostridium difficile skin contamination in patients with C. difficile-associated disease. Clin Infect Dis 2008; 46:447.</a></li><li><a class="nounderline abstract_t">Shaughnessy MK, Micielli RL, DePestel DD, et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol 2011; 32:201.</a></li><li><a class="nounderline abstract_t">Curry SR, Muto CA, Schlackman JL, et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 2013; 57:1094.</a></li><li><a class="nounderline abstract_t">Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013; 369:1195.</a></li><li><a class="nounderline abstract_t">Kong LY, Eyre DW, Corbeil J, et al. Clostridium difficile: Investigating Transmission Patterns Between Infected and Colonized Patients Using Whole Genome Sequencing. Clin Infect Dis 2019; 68:204.</a></li><li><a class="nounderline abstract_t">Kociolek LK, Gerding DN, Espinosa RO, et al. Clostridium difficile Whole Genome Sequencing Reveals Limited Transmission Among Symptomatic Children: A Single-Center Analysis. Clin Infect Dis 2018; 67:229.</a></li><li><a class="nounderline abstract_t">Robilotti E, Huang W, Babady NE, et al. Transmission of Clostridioides difficile infection (CDI) from patients less than 3 years of age in a pediatric oncology setting. Infect Control Hosp Epidemiol 2020; 41:233.</a></li><li><a class="nounderline abstract_t">Adams DJ, Eberly MD, Rajnik M, Nylund CM. Risk Factors for Community-Associated Clostridium difficile Infection in Children. J Pediatr 2017; 186:105.</a></li><li><a class="nounderline abstract_t">Toltzis P, Kim J, Dul M, et al. Presence of the epidemic North American Pulsed Field type 1 Clostridium difficile strain in hospitalized children. J Pediatr 2009; 154:607.</a></li><li><a class="nounderline abstract_t">Kociolek LK, Patel SJ, Shulman ST, Gerding DN. Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study. Infect Control Hosp Epidemiol 2015; 36:445.</a></li><li><a class="nounderline abstract_t">Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68:1951.</a></li><li><a class="nounderline abstract_t">Sandora TJ, Fung M, Flaherty K, et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011; 30:580.</a></li><li><a class="nounderline abstract_t">Tamma PD, Sandora TJ. Clostridium difficile Infection in Children: Current State and Unanswered Questions. J Pediatric Infect Dis Soc 2012; 1:230.</a></li><li><a class="nounderline abstract_t">Owens RC Jr, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1:S19.</a></li><li><a class="nounderline abstract_t">Miranda-Katz M, Parmar D, Dang R, et al. Epidemiology and Risk Factors for Community Associated Clostridioides difficile in Children. J Pediatr 2020; 221:99.</a></li><li><a class="nounderline abstract_t">Tariq R, Cho J, Kapoor S, et al. Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. Clin Infect Dis 2018; 66:514.</a></li><li><a class="nounderline abstract_t">Nicholson MR, Thomsen IP, Slaughter JC, et al. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr 2015; 60:18.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201.</a></li><li><a class="nounderline abstract_t">Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010; 31:754.</a></li><li><a class="nounderline abstract_t">Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. J Pediatr 2014; 165:979.</a></li><li><a class="nounderline abstract_t">Freedberg DE, Lamousé-Smith ES, Lightdale JR, et al. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis 2015; 61:912.</a></li><li><a class="nounderline abstract_t">Mehta P, Nahass RG, Brunetti L. Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis. Clin Infect Dis 2021; 73:e62.</a></li><li><a class="nounderline abstract_t">Tai E, Richardson LC, Townsend J, et al. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J 2011; 30:610.</a></li><li><a class="nounderline abstract_t">de Blank P, Zaoutis T, Fisher B, et al. Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr 2013; 163:699.</a></li><li><a class="nounderline abstract_t">Willis DN, Huang FS, Elward AM, et al. Clostridioides difficile Infections in Inpatient Pediatric Oncology Patients: A Cohort Study Evaluating Risk Factors and Associated Outcomes. J Pediatric Infect Dis Soc 2021; 10:302.</a></li><li><a class="nounderline abstract_t">Parmar D, Dang R, Miranda-Katz M, et al. Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children. Pediatr Infect Dis J 2019; 38:1073.</a></li><li><a class="nounderline abstract_t">Fisher BT, Sammons JS, Li Y, et al. Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. J Pediatric Infect Dis Soc 2014; 3:329.</a></li><li><a class="nounderline abstract_t">Nicholson MR, Osgood CL, Acra SA, Edwards KM. Clostridium difficile infection in the pediatric transplant patient. Pediatr Transplant 2015; 19:792.</a></li><li><a class="nounderline abstract_t">Boyle NM, Magaret A, Stednick Z, et al. Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients. Antimicrob Resist Infect Control 2015; 4:41.</a></li><li><a class="nounderline abstract_t">Pant C, Deshpande A, Desai M, et al. Outcomes of Clostridium difficile infection in pediatric solid organ transplant recipients. Transpl Infect Dis 2016; 18:31.</a></li><li><a class="nounderline abstract_t">Ochfeld E, Balmert LC, Patel SJ, et al. Risk factors for Clostridioides (Clostridium) difficile infection following solid organ transplantation in children. Transpl Infect Dis 2019; 21:e13149.</a></li><li><a class="nounderline abstract_t">Duclaux-Loras R, Berthiller J, Ferroni A, et al. Clostridium difficile: A Frequent Infection in Children After Intestinal Transplantation. Transplantation 2020; 104:197.</a></li><li><a class="nounderline abstract_t">Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154:854.</a></li><li><a class="nounderline abstract_t">Sandberg KC, Davis MM, Gebremariam A, Adler J. Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997-2011. J Pediatr Gastroenterol Nutr 2015; 60:486.</a></li><li><a class="nounderline abstract_t">Martinelli M, Strisciuglio C, Veres G, et al. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study. Inflamm Bowel Dis 2014; 20:2219.</a></li><li><a class="nounderline abstract_t">El-Matary W, Nugent Z, Yu BN, et al. Trends and Predictors of Clostridium difficile Infection among Children: A Canadian Population-Based Study. J Pediatr 2019; 206:20.</a></li><li><a class="nounderline abstract_t">Yahav J, Samra Z, Blau H, et al. Helicobacter pylori and Clostridium difficile in cystic fibrosis patients. Dig Dis Sci 2006; 51:2274.</a></li><li><a class="nounderline abstract_t">Rivlin J, Lerner A, Augarten A, et al. Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis. J Pediatr 1998; 132:177.</a></li><li><a class="nounderline abstract_t">Hussain SZ, Chu C, Greenberg DP, et al. Clostridium difficile colitis in children with cystic fibrosis. Dig Dis Sci 2004; 49:116.</a></li><li><a class="nounderline abstract_t">Yates B, Murphy DM, Fisher AJ, et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. Thorax 2007; 62:554.</a></li><li><a class="nounderline abstract_t">Urushihara N, Kohno S, Hasegawa S. Pseudomembranous enterocolitis and hemorrhagic necrotizing enterocolitis in Hirschsprung's disease. Surg Today 1994; 24:221.</a></li><li><a class="nounderline abstract_t">Mc Laughlin D, Friedmacher F, Puri P. The impact of Clostridium difficile on paediatric surgical practice: a systematic review. Pediatr Surg Int 2014; 30:853.</a></li><li><a class="nounderline abstract_t">Williams RN, Hemingway D, Miller AS. Enteral Clostridium difficile, an emerging cause for high-output ileostomy. J Clin Pathol 2009; 62:951.</a></li><li><a class="nounderline abstract_t">Causey MW, Spencer MP, Steele SR. Clostridium difficile enteritis after colectomy. Am Surg 2009; 75:1203.</a></li></ol></div><div id="topicVersionRevision">Topic 6041 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25714160" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Burden of Clostridium difficile infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047244" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20350373" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clostridium difficile infections among hospitalized children, United States, 1997-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21199971" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clostridium difficile infection in hospitalized children in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23546535" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clostridium difficile infection in the hospitalized pediatric population: increasing trend in disease incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17552108" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clostridium difficile in retail ground meat, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25582646" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Potential sources of Clostridium difficile in human infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19402979" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clostridium difficile in ready-to-eat salads, Scotland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21919997" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clostridium difficile in Dutch animals: their presence, characteristics and similarities with human isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657158" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Investigation of potentially pathogenic Clostridium difficile contamination in household environs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7217711" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19329224" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Contamination of pet therapy dogs with MRSA and Clostridium difficile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831824" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clostridium difficile toxins: mechanism of action and role in disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2507823" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clostridium difficile toxin A. Interactions with mucus and early sequential histopathologic effects in rabbit small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738167" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252482" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Toxin B is essential for virulence of Clostridium difficile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10878068" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16857405" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Toxin A-negative, toxin B-positive Clostridium difficile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182895" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322603" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : An epidemic, toxin gene-variant strain of Clostridium difficile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25875259" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28520953" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evolving Insights Into the Epidemiology and Control of Clostridium difficile in Hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10666429" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213096" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28121498" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25942722" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500319" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1325998" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18039894" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18039894" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322602" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322602" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408679" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The epidemiology of Clostridium difficile infection in children: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17265394" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recommendations for surveillance of Clostridium difficile-associated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590748" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clostridium difficile infection among children across diverse US geographic locations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24046303" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Distinguishing community-associated from hospital-associated Clostridium difficile infections in children: implications for public health surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361022" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A hospital-based study of the clinical characteristics of Clostridium difficile infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23300561" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24915226" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The prediction of complicated Clostridium difficile infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22031485" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk factors and outcomes associated with severe clostridium difficile infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20512057" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664931" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clostridium difficile in children: colonisation and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107991" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The role of Clostridium difficile in the paediatric and neonatal gut - a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22843784" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24172156" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Toxin-producing Clostridium difficile strains as long-term gut colonizers in healthy infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393454" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevalence and diversity of Clostridium difficile strains in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34338715" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence of Detection of Clostridioides difficile Among Asymptomatic Children: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28813461" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7239125" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7068220" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31253983" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Natural Clostridioides difficile Toxin Immunization in Colonized Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940476" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Molecular epidemiology of Clostridium difficile strains in children compared with that of strains circulating in adults with Clostridium difficile-associated infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434341" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A case-control study of community-associated Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25247582" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Similar proportions of stool specimens from hospitalized children with and without diarrhea test positive for Clostridium difficile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427457" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A prospective study of Clostridium difficile infection and colonization in pediatric oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145927" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17630999" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8579084" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181742" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clostridium difficile skin contamination in patients with C. difficile-associated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460503" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Evaluation of hospital room assignment and acquisition of Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23881150" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24066741" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Diverse sources of C. difficile infection identified on whole-genome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29846557" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clostridium difficile: Investigating Transmission Patterns Between Infected and Colonized Patients Using Whole Genome Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370348" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clostridium difficile Whole Genome Sequencing Reveals Limited Transmission Among Symptomatic Children: A Single-Center Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31896369" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Transmission of Clostridioides difficile infection (CDI) from patients less than 3 years of age in a pediatric oncology setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28396027" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk Factors for Community-Associated Clostridium difficile Infection in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324222" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Presence of the epidemic North American Pulsed Field type 1 Clostridium difficile strain in hospitalized children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25782900" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23620467" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Community-associated Clostridium difficile infection and antibiotics: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233782" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Epidemiology and risk factors for Clostridium difficile infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687578" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clostridium difficile Infection in Children: Current State and Unanswered Questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18177218" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Antimicrobial-associated risk factors for Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171559" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Epidemiology and Risk Factors for Community Associated Clostridioides difficile in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29401273" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199038" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Novel risk factors for recurrent Clostridium difficile infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319813" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047577" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25112692" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Association of Clostridium difficile infections with acid suppression medications in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26060292" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32386313" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21206395" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clostridium difficile infection among children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23477996" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766672" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clostridioides difficile Infections in Inpatient Pediatric Oncology Patients: A Cohort Study Evaluating Risk Factors and Associated Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31626042" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26625453" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Variation in Risk of Hospital-Onset Clostridium difficile Infection Acrossβ-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26403484" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clostridium difficile infection in the pediatric transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26473030" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538348" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Outcomes of Clostridium difficile infection in pediatric solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31332916" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk factors for Clostridioides (Clostridium) difficile infection following solid organ transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31205257" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Clostridium difficile: A Frequent Infection in Children After Intestinal Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230908" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Impact of Clostridium difficile infection on pediatric inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25419679" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25268634" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30448272" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Trends and Predictors of Clostridium difficile Infection among Children: A Canadian Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17078007" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Helicobacter pylori and Clostridium difficile in cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9470027" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14992445" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Clostridium difficile colitis in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601087" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8003864" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pseudomembranous enterocolitis and hemorrhagic necrotizing enterocolitis in Hirschsprung's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25008231" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The impact of Clostridium difficile on paediatric surgical practice: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447832" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Enteral Clostridium difficile, an emerging cause for high-output ileostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19999913" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clostridium difficile enteritis after colectomy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
